Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution (A61P41)

A   Human necessities(312083)
A61P41                 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution(274)

ethod for inguinal hernia treatment // 2641368
FIELD: medicine.SUBSTANCE: in the medial part of the patient's inguinal canal lying on the back, a polymerizable mixture consisting of three solutions A, B and C is introduced by injection through the needle. Solution A is a solution of a copolymer of acrylamide and hydroxysuccinimide ester of acrylic acid. Solution B is a solution of 1,4-butanediamine and succinic acid. Solution C is a solution of sodium hydrogencarbonate. The molar ratio of acrylamide and hydroxysuccinimide ester of acrylic acid in the copolymer is selected in the range of 9:1 to 7:3, the molar ratio of 1,4-butanediamine to succinic acid in solution B is selected in the range of 4:1 to 1:1. The concentration of solution A was selected from the mass concentration of the copolymer in solution A in the range 21.8-26.3 g/l. The concentration of solution B is: for 1,4-butanediamine - about 22.0 g/l, for succinic acid - in the range of 7.4-29.5 g/l. The concentration of solution C is in the range of 0.6-1.1 mol/l. The ratio of the quantity of solutions A and B is chosen so that the molar ratio of hydroxysuccinimide ester of acrylic acid in the copolymer and 1,4-butanediamine does not exceed 2:1. The ratio of the quantity of solutions B and C is selected from the condition that the molar ratio of sodium hydrogencarbonate and succinic acid is not less than 2:1. The mixture is prepared by successively mixing solutions A and B and then solution C. Then, the prepared mixture is injected until the inguinal canal is filled and the patient is left in the indicated position until the polymerization of the mixture introduced into the inguinal channel is completed.EFFECT: invention allows minimally invasive elimination of hernial protrusion, reliable closure of hernial gates, and prevention of recurrent inguinal hernia.7 cl, 9 dwg
ethod for treating soft tissue abscesses in experiment // 2639595
FIELD: medicine.SUBSTANCE: treatment method comprises lancing of the abscess, evacuation of the contents and laser destruction of intracavitary tissue sequester. Additionally, the cavity is filled with a combined 1% solution of zinc oxide nanoparticles and 1% solution of Eplan preparation daily until the abscess is healed.EFFECT: method provides stimulation of reparative processes of tissues, does not require special skills and expensive equipment, the method is minimum traumatic, it allows to achieve complete obliteration of the cavity on the 10th day of treatment.1 ex, 1 tbl, 3 dwg

ethod for observation of fatty tissue // 2638642
FIELD: medicine.SUBSTANCE: in the first embodiment of the method, an optical antireflective agent is applied to the fatty tissue and the fatty tissue is heated. In the second embodiment of the method, a heated optical antireflective agent is applied to the fatty tissue. Observation inside the fatty tissue is performed, in which the optical antireflective agent penetrated. The target heating temperature is a temperature at which the refractive index of the fatty tissue becomes close to the refractive index of the optical antireflective agent.EFFECT: improvement of the visibility of a blood vessel that passes inside or under fatty tissue, due to the creation of conditions for low light flare by fatty tissue and improvement of penetration of antireflective agent in fatty tissue, which reduces the complexity of the surgical procedure of removing fatty tissue.5 cl, 10 dwg
ethod of surgical treatment of patients with arnold-chiari malformation // 2635862
FIELD: medicine.SUBSTANCE: Y-shaped dissection of the dura mater (DM) is carried out before the release of cerebellum tonsils and subsequent plastication of the formed defect. Wherein, additional plastic is performed on artificial DM. To do this, the edges of DM and the formed flap of artificial DM are glued with the help of Tissukol Kit or BioGlue adhesive compositions, which are applied with the help of a doveplication system and an application needle.EFFECT: method helps to reduce postoperative complications, which is achieved by performing additional plastics of dura mater.1 cl
ethod for intestine peristalsis stimulation in complex treatment of abdominal infection // 2634630
FIELD: medicine.SUBSTANCE: intraportal administration of ozonized saline and perfluorane is performed. At that, after peritonitis source removal, nasointestinal intubation, lavage and abdominal cavity drainage prior to medium wound suturing, recanalization and catheterization of the umbilical vein are performed. Then, on day 1-3 after the operation, intraportal infusion of serotonin adipate is additionally performed by 40 drops per minute at a dose of 20-30 to 40-60 mg/day, depending on the phase of pathological process development and the severity of patient's condition.EFFECT: increased clinical efficacy of intestinal peristalsis stimulation.6 tbl, 1 ex
ethod of obtaining antimiscular film material based on derivatives of cellulose // 2634577
FIELD: chemistry.SUBSTANCE: method comprises dissolving hydroxyethyl cellulose in water in the presence of a crosslinking agent - glutaric acid in an amount of 10-50 wt % of the polymer, drying the resulting film in air at a temperature of 18-25°C and subsequent heat treatment at a temperature of 98-105°C for 180-360 minutes.EFFECT: simplification and improvement of the process safety, lowering of the heat treatment temperature, longer film stay in the zone of postoperative recovery, and an increase in the anti-spasm effect.1 tbl, 14 ex
ethod for treating acute widespread purulent peritonitis // 2631561
FIELD: medicine.SUBSTANCE: intra-abdominal sanation and intestinal peritoneal-intestinal lavage is carried out with the use of ozone under the control of intra-abdominal pressure. At the same time, sanation of the abdominal cavity is carred out with 1500-2000 ml of ozonized physiological solution with an ozone concentration of 3-6 mg/l and 500-800 ml of ozone-oxygen mixture with an ozone concentration of 15-20 mg/l. Intestinal lavage is carried out with 200-400 ml of ozonized physiological solution with an ozone concentration of 3-4 mg/l under the control of intra-abdominal pressure.EFFECT: method allows to prevent a critical increase in intra-abdominal pressure, has a pronounced sanative and biostimulating effect, accelerates recovery of motor-evacuator function of the gastrointestinal tract, reduces the intensity of bacterial contamination of the abdominal cavity and intestines, reduces endogenous intoxication, and does not cause adverse reactions.1 dwg
ethod for production of anti-adhesion film material based on carboxymethyl cellulose // 2629842
FIELD: medicine.SUBSTANCE: method for anti-adhesion film material production involves dissolution of the polymer, represented by a mixture of carboxymethyl cellulose and hydroxyethyl cellulose in a ratio of 8:2 to 3:7, in water in the presence of a glutaric acid structurant in an amount of 10-50% by polymers weight, drying at 18-25°C and heat treatment in air at 98-105°C for 180-360 minutes.EFFECT: invention ensures a longer film stay in the postoperative recovery zone and an increase in the ant-adhesion effect, simplification and improved safety of the technological process and lower temperature of heat treatment.1 tbl, 15 ex
ethod for production of anti-adhesion film material based on carboxymethyl cellulose // 2629841
FIELD: medicine.SUBSTANCE: invention relates to a method for preparation of an anti-adhesion film material comprising dissolution of a polymer, represented by a mixture of carboxymethyl cellulose and hydroxyethyl cellulose in a ratio of 8:2 to 3:7, in water in the presence of a 1,6-hexanediol diglutar ester structurant in an amount of 10-50% by polymer weight, drying at 18-25°C and heat treatment in air at 98-105°C for 180-360 minutes.EFFECT: ensures a longer film stay in the postoperative recovery zone and an increase in the ant-adhesion effect, simplification and improved safety of the technological process and lower temperature of heat treatment.16 ex, 1 tbl
ethod for tubular bone defects plastic in patients with chronic osteomyelitis // 2627815
FIELD: medicine.SUBSTANCE: sanation of the osteomyelitis focus, plastic of the bone cavity by platelet-enriched autoplasm and biomaterial are performed. At that, prior to plastic surgery, a thin needle is rotated in various directions to provide revascularizing osteoperforation of the bone cavity walls along the edge of which the bioplastic membrane "Collost" is fixed with transossal sutures, without tightening the threads. The intact autologous muscle tissue is taken, which is ground to the state of muscle mince. It is mixed with the platelet-enriched autoplasma and densely placed in the bone cavity, which is sealed with the bioplastic membrane "Collost", tightening the threads of the transossal sutures.EFFECT: method allows to ensure sealing of the plastic area of tubular bones defects in patients with chronic osteomyelitis, to create optimal conditions for reparative processes of bone tissue.1 ex
ethod for chronic wounds treatment // 2627814
FIELD: medicine.SUBSTANCE: pre-sanitized wound is covered with a bioplastic membrane "Collost", fixing it with separate nodal sutures at a distance of 0.3 mm from each other. Near the upper edge of the wound, a subclavian catheter is installed, the tube of which is up to 1 mm and length is up to 150 mm . This tube is pre-perforated and inserted under the membrane through the upper edge of the wound. The membrane is covered with an antiseptic dressing so that the head with the subclavian catheter plug remains above it for daily single administration of platelet-enriched plasma, which is obtained by taking 20 ml of blood from the peripheral vein, which is centrifuged for 15 minutes at 4000 revolutions. Then, the liquid part of plasma is placed in a sterile tube without a stabiliser and is centrifuged at 3500 rpm for 15 minutes to obtain platelet-enriched plasma with a volume of up to 2 ml, which is injected through the subclavian catheter no later than 10 minutes after its production. The antiseptic bandage on the wound is replaced once in 5-7 days.EFFECT: method allows to increase the effectiveness of chronic wounds local treatment, reduce trauma, simplify wound treatment and care.1 ex
ethod for getting surgical barrier material based on polysaccharides // 2627666
FIELD: biotechnology.SUBSTANCE: to get the barrier material using apple pectin and chitosan, the last preferably with 38-100% deacetylation degree and molecular weight 25-230 kDa. According to the method, apple pectin is dissolved in water, calcium chloride or chitosan with addition of calcium chloride is dissolved in 0.25% aqueous solution of acetic acid, the resulting solution is frozen at minus 18±1°C, then layer the apple pectin solution to it. Mass ratio of pectin and chitosan is 3:1. The frozen solution is slowly thawed for 4-6 hours at a temperature of 15-22°C. The formed surgical barrier material is freeze-dried and then sterilized by UV irradiation.EFFECT: surgical barrier material in the form of cryogel has biocompatible properties, a period of biodegradation not exceeding 24 hours, and allows effective prevention of adhesions formation in the experiment.2 cl, 1 dwg, 2 tbl, 5 ex
Stimulus-sensitive material and medical material containing it // 2625761
FIELD: medicine.SUBSTANCE: temperature-sensitive medical anti-solder material contains a temperature-sensitive polymer in an amount of 10-50 wt %, fibers in an amount of 0.5-10 wt % and water, where the fibers dispersed in the temperature sensitive polymer have a number-average diameter of 1 to 900 nm. The temperature-sensitive polymer and fiber have a common basic chemical structure selected from the following combinations: the fiber includes lactic acid units -O-CH(CH3)-CO-, while the temperature-sensitive polymer includes lactic acid units -O-CH(CH3)-CO-, or the fiber includes nylon 6 -CH2CH2CH2CH2CH2-CO-NH-. The temperature-sensitive polymer includes amide units -CO-NH-, and the weight ratio of the temperature-sensitive polymer to the fibers is 5 to 100. The invention provides creation of a material in which both ease of use and mechanical properties are achieved at the same time.EFFECT: invention is favorable for sol-gel transition of between the liquid and solid state.10 cl, 2 tbl, 13 ex
ethod for chronic haemorrhoid low-invasive treatment // 2625277
FIELD: medicine.SUBSTANCE: desarterisation of internal hemorrhoids and their subsequent sclerosing is performed. To carry out internal hemorrhoids desarterisation, each terminal branch of the upper rectal artery feeding the corresponding hemorrhoidal node is stitched at its base with a resorbable suture material with a Z-shaped suture. Sclerotherapy is performed with Ethoxysclerol, which, at a dose of 10-20 mg, is first introduced into the "vascular pedicle", then into the cavernous tissue of each internal hemorrhoidal node using an ultrasound "specialized needle" for "Prokson" ultrasonic treatment of biological tissues. The ultrasonic exposure is provided in the output power mode of the "Prokson" generator of 09 units and "specialized needle" ultrasonic action time equal to 20 s for each hemorrhoidal node.EFFECT: elimination of postoperative pain syndrome and a significant decrease in the number of disease relapses.1 cl

Compounds for adhesion treatment or prevention, pharmaceutical compositions based thereon and method for adhesion process prevention and treatment // 2624228
FIELD: pharmacology.SUBSTANCE: invention discloses pharmaceutical compositions containing an effective amount of SB203580 substance or one of the compounds of type (I) to (VII) or combinations thereof, and a pharmaceutically acceptable carrier, diluent or excipient. Also, application of structures of type (I) - (VII) as a means having anti-adhesion activity is disclosed. In addition, a method for prevention and/or treatment of a disease or condition with a possibility of adhesions formation and/or growth, that allows dispensing without additional administration of drug in the postoperative period is disclosed.EFFECT: possibility of use for treatment or prevention of adhesion.14 cl, 16 ex, 10 dwg
eans for peritoneal adhesions treatment // 2621131
FIELD: pharmacology.SUBSTANCE: means for treatment of peritoneal adhesion for ingestion, which contains an aqueous extract from the rhizomes of sweet flag, common St. John's wort herb, common licorice roots, obtained from the rhizomes of sweet flag, common St. John's wort herb, common licorice roots, drinking water, taken at a certain component content.EFFECT: agent is effective for peritoneal adhesions treatment.2 ex
ethod for fat embolism syndrome prevention for patients with multiple injuries in case of long bones fractures // 2620858
FIELD: medicine.SUBSTANCE: prevention of fat embolism syndrome (FES) is carried out according to the following scheme: hematoma is punctured in the fracture area, long bones are immobilized using extrafocal osteosynthesis by means of a rod apparatus according to the minimally invasive immobilization osteosynthesis principle. Then, 200 mg of mexidol solution per 200 ml of isotonic solution is administered intravenously twice a day for 3 days, and for the subsequent 2 days, 200 mg 2 times a day, intramuscularly, 40 ml of Essentiale per day, intravenously, 5000 units of heparin 4 times a day, subcutaneously, under the control of blood clotting for 5 days.EFFECT: invention improves efficiency of fat embolism syndrome prevention for victims with polytrauma with long bonesfractures.1 ex
Device for cell fraction isolation from human and animal tissues, and method of its application // 2620304
FIELD: biotechnology.SUBSTANCE: device is proposed for isolation of stromal-vascular fraction from human and animal tissues, a method of cellular fractions isolation using this device, stromal-vascular fraction of adipose tissue to create tissue-engineering structures and for use as a cell autograft, and a method of tissue treatment, repair or replacement using stromal-vascular fraction of adipose tissue. The device includes a sealed container for tissue processing with a system of channels and nozzles-adapters. Also, this container has a conical shape and is divided into two chambers by the microfilter system. One chamber serves for tissue treatment and the other for cells concentrating. The container also has channels within the wall, wherein one of the channel comes out into the first chamber and the other into the second chamber. The method comprises decanting, washing and lipoaspirate enzymatic treatment, centrifugation, filtration through microfilters, followed by removal of fat impurities and stromal tissue, as well as secondary washing and cell fraction concentration.EFFECT: controlled isolation of stromal-vascular fraction of adipose tissue, characterized by high cell survival, lack of debris and residues of stromal and adipose tissue and circulating blood cells, and low concentration of residual enzyme activity.8 cl, 7 dwg, 1 tbl
ethod for salivary gland tumour surgical treatment // 2618165
FIELD: medicine.SUBSTANCE: access to the salivary gland is obtained by one of the standard skin incisions in prootic area, based on tumour location. The affected part is seected and excised within healthy tissues. In this case, after removal of the affected part of the salivary gland, salivary gland slices visible in the surgical wound are infiltrated with type A botulinum toxin solution, 1-2 units in each slice. Soft tissue is sutured, and sutures are imposed on the skin, an aseptic bandage is applied.EFFECT: reduced time of treatment and rehabilitation by accelerating the regeneration of the post-operative wound, prevention of salivation in early postoperative period and salivary fistula formation in late postoperative period.4 ex

Chemical pleurodesis method // 2616271
FIELD: medicine.SUBSTANCE: processing of the parietal and visceral pleura during thoracoscopy is performed with peroxide solutionat a concentration of 5.5-6.5%.EFFECT: reliable adhesions in the pleural cavity with preferential formation of fibrous adhesions with lymphohistiocytic type of infiltration without expressed inflammatory changes in the lung tissue.4 dwg, 3 tbl, 2 ex
ethod for maxillofacial region infantile hemangioma treatment for children // 2615284
FIELD: medicine.SUBSTANCE: propranolol is administered orally at the initial dosage of 1 mg/kg/day. Three hemangioma sclerosing operations with 70% ethanol and 2% lidocaine in a ratio of 2:1 are performed additionally once every 3 days. Xclerosing course is repeated 1 time per month to the stage of hemangioma regress, which is recorded according to the results of anthropometry, visual evaluation, and hemangioma ultrasounding results.EFFECT: reduced mean number of treatment sessions required for hemangioma regress, at reduced complications, simple and minimally invasive treatment.1 ex
ethod for donor cornea processing with double-sided uv crosslinking for keratoprosthetics of complicated vascular leucomas of category 4-5 // 2613442
FIELD: medicine.SUBSTANCE: donor cornea is placed in a preserving environment for 1 hour. Then the donor cornea is moved into a sterile container and treated with ultraviolet light from one side of the cornea with a wavelength of 365 nm, power of 3 mW/sq. cm. Instillation of 1 drop of 0.1% riboflavin solution (first processing on cornea is performed very 5 minutes. After processing, the donor cornea is treated with ultraviolet light from the opposite side similarly to the first treatment. The preserving environment contains riboflavin mononucleotide, dextran, glutathione, sodium chloride and purified distilled water, in the following ratio, wt %: riboflavin mononucleotide - 0.1, dextran - 10.0, glutathione - 0.09, sodium chloride - 0. 9, purified distilled water - the rest.EFFECT: obtaining of donor cornea with increased biochemical, biomechanical and strength properties, thereby reducing the risk of cornea necrosis.2 cl, 1 ex
ethod for catheterization and block of retroperitoneal nerve formations // 2602173
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to surgery, and, it can be used for catheterization and block of retroperitoneal nerve formations. For this purpose, under control of ultrasonic examination with parallel Doppler sonography soft tissues centesis of the abdominal wall is punctured at the point, located at boundary of outer and middle one-third line connecting the outer upper spine of the left iliac bone with symphysis. Catheter is inserted in the mesentery of sigmoid colon roots. Then 80.0-100.0 ml of local anesthetic is introduced by the catheter.EFFECT: method provides higher efficiency of retroperitoneal nerve formations block, innervating sigmoid colon, rectosigmoid transition and zone of pararectal plexus for preventive measures and treatment of disorder of motor and intestinal evacuation functions with minimal injuries of catheterization due to optimal selection of puncture point and dose of introduced anesthetic.1 cl, 1 ex
ethod for restoration of rectal closing apparatus // 2600851
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to coloproctology, and can be used for restoration of rectal closing apparatus. For this purpose, the graft is being once introduced into the soft tissues of the para-anal area, graft comprises a cell mass of the autologous bone-marrow punctate. Introduced graft also comprises a biodegradable heterogeneous hydrogel Sphero®GEL medium. Ratio of volume of induced cell mass and volume of hydrogel Sphero®GEL medium is 1:1. After that, this area is being exposed with bipolar symmetric fluctuating current of the therapeutic course of 10 daily procedures. One electrode is being placed on the lumbar spine, and the second one - in the anal area. Current intensity is being gradually increased to 5-10 mA to observe visible muscle contraction.EFFECT: such a method provides restoration of muscular structures of rectal closing apparatus, higher efficiency of the autohemotherapy and reduced traumatism while treating the given pathology as a result of increased viability of the introduced cell mass and stimulation of regenerative processes in the introducing area for the necessary tissue restoration period.1 cl, 1 ex

ethod of anesthesia risk reducing during laparoscopic cholecystectomy // 2594976
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to anesthesiology, and can be used to reduce the anaesthetic risk during laparoscopic cholecystectomy. For this purpose prior to the surgery patient's resistance to oxidative stress is measured. Patient is tested on a stabilographic platform and is calculated P=95Fy60-70Fx60+4V+W, where Fy60 and Fx60 - 60% quantile of spectral density power of pressure oscillation frontal and sagittal planes (Hz), V is the average speed of the centre of pressure (mm/s), W - patient's weight (kg). Thiopental sodium is used during initial anaesthesia if p < 130, during perioperative therapy solution methylethyl pyridinol hydrochloride is used and solution containing sodium fumarate and sodium chlorides of potassium and magnesium. If 130≤P≤150 ketamine is used during initial anaesthesia, during perioperative therapy solution methylethyl pyridinol hydrochloride is used and solution containing sodium fumarate and sodium chlorides of potassium and magnesium. If P > 150 propofol is used during initial anaesthesia, while supporting anaesthesia - sevorane without perioperative antioxidant therapy.EFFECT: method provides safety, efficiency and cost lowering of the preoperative testing, leading to the effective correction of antioxidant protection in laparoscopic cholecystectomy.1 cl, 2 tbl

ethod for intraportal ozone therapy in patients with widespread peritonitis // 2594512
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to surgery, and can be applied to intraportal ozone therapy in patients with widespread peritonitis. Ozonation is carried out by means of medical ozone generator with ozone concentration in ozone-oxygen mixture not less than 1,000 mcg/l. After eliminating source of peritonitis, carrying out naso-intestinal intubation, irrigation, and drainage of abdominal cavity, before closure of middle wound, recanalisation and catheterisation of umbilical vein is performed with cannulation. Then intraportal infusion of ozonised perfluoran is performed on days 1 and 2 after operation by drop method at rate 40 drops per minute. Then on days 3 to 5 intraportal infusion is performed with ozonised physiological saline.EFFECT: method ensures reduction of endogenous intoxication in patients with diffuse peritonitis and reduced number of postoperative complications and postoperative mortality.1 cl, 3 tbl, 5 dwg, 1 ex
ethod for prevention of pyoinflammatory complications following surgery in maxillofacial area // 2593901
FIELD: medicine. SUBSTANCE: invention can be used for prevention of pyoinflammatory complications following surgery in maxillofacial area. For this purpose, prior to the surgery risk factors of pyoinflammatory complications are detected in patient, and prognostic coefficients are evaluated in points. Thus, age over 70 - 2 points, hypotrophy - 5 points, obesity - 5 points, diabetes mellitus - 5 points, drug habit - 5 points, alcohol abuse - 5 points, chronic renal failure - 5 points; chronic liver failure - 5 points, chronic cardiac failure -5 points, cancer - 5 points, other chronic diseases - 3 points, immunosuppressive therapy - 5 points, long-term ingestion of glucocorticosteroids - 5 points, chemotherapy of cancer - 5 points , radiation therapy - 5 points, infected damage in the area of surgical intervention - 5 points, implantation of foreign materials - 5 points, drainage of postoperative wound - 5 points. In the absence of risk factors, the risk of pyoinflammatory complications is evaluated as low. Only antibiotic prophylaxis is carries out. For this purpose, 30 minutes before the beginning of surgery 2.0 g of ceftriaxone is injected intravenously, then in the postoperative period during 5 days 1.0 gram intramuscularly 2 times a day. If total prognostic score is 2-10 points, there in an average risk of pyoinflammatory complications. Note that antibiotic prophylaxis is added with nutritional support. For this purpose the postoperative period involves intake of Nutridrink nutrient mixture as sip feed by 200.0 ml q.i.d. within 3 weeks. If total prognostic score is over 10 points, the risk of pyoinflammatory complications is evaluated as high. In such case antibiotic prophylaxis and nutritional support is added with immune correction. For this purpose Imunofan is additionally injected in dosage of 1.0 ml intramuscularly once a day. First injection of the preparation is carried out 2 hours before the surgery and continue for 10 days after the surgery. EFFECT: method provides reducing a risk of pyoinflammatory complications by the differentiated determination of indications and scope of arrangements in patients after surgical treatment in maxillofacial area. 1 cl, 3 ex
Compounds, pharmaceutical compositions and method for prevention and treatment of adhesive process // 2582975
FIELD: pharmaceuticals.SUBSTANCE: invention refers to pharmacy, clinical and experimental medicine and veterinary science, particularly to inhibitory compounds of a p38 MAP kinase with a structure of type (I)-(VII). Invention discloses pharmaceutical compositions containing an effective amount of substance SB 203580 (4-(4-fluorophenyl)-2-(4-methylsulphenylphenyl)-5-(4-pyridyl)-1H-imidazole), or one of compounds of type (I)-(VII), or combinations thereof and a pharmaceutically acceptable carrier, thinner or excipient.EFFECT: invention can be used for treating or preventing adhesion.10 cl, 16 ex, 9 dwg

edicinal product with particle-free coating releasing active substance // 2578422
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, specifically to a body-contacting medicinal product such as a short-term implant and a long-term implant coated by at least one layer, which contains a molecular-disperse distributed or dissolved active substance in at least one carrier and optionally one or more additives; the above at least one layer is formed of abrasion-resistant solution in the form of a over-cooled melt, which optionally contains a crystallisation inhibitor.EFFECT: coated implant makes it possible to transfer the active substance to vascular walls effectively and with no particles formed.10 cl, 18 ex

Bioresorbable wound dressing // 2577155
FIELD: medicine.SUBSTANCE: invention represents a non-woven fabric applicable for GDF-5 protein delivery and containing the fibres of a fibrous raw material comprising bioresorbable and/or biocompatible polymers; these fibres contain GDF-5 protein including a cystine-knot domain with an amino acid identity of at least 60% to 102 aa-cystine-knot domain of human GDF-5 relevant to amino acids 400-501 SEQ ID NO: 2. The above GDF-5 protein is distributed in the fibres. The invention also refers to the wound dressing, wound pad and implant that contain the above non-woven fabric.EFFECT: higher efficacy.17 cl, 9 dwg, 4 ex
Producing animal derma graft with using sodium sulphide solution // 2575831
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutics and concerns a method for producing a graft of animal's derma, preferentially swine derma, including the following stages: a) preparing the animal's derma; b) processing the animal's derma with an aqueous alkaline solution containing 0.01 to 1.5 wt % of sodium sulphide; c) processing the derma once or more than once with an aqueous saline solution; d) processing the derma once or more than once with aqueous hydrogen peroxide; e) dehydrating the derma. Another object of the invention is a graft produced by the above method, and using it in surgical management of hernias or for treating an abdominal wound disruption.EFFECT: group of inventions provides the simple and fast method for producing the graft, which has the structure significantly identical to that of native derma.12 cl, 1 tbl, 1 ex
ethod of treating sepsis in treating abdominal organs complicated by hepatic failure // 2572019
FIELD: medicine.SUBSTANCE: method involves a selective sorption of endotoxin through a vascular access, and an infusion therapy with administering an antibiotic. The absorption is preceded by an infusion of 10% albumin into a portal vein in an amount of 100 ml. The infusion is followed by the selective sorption of gram-negative flora endotoxins through the portal vein 30-45 minutes after the albumin infusion is completed. The gram-negative flora active antibiotic is infused into the portal vein during the whole period of the sorption; after the procedure is completed, a hepatoprotector is administered into the portal vein.EFFECT: method enables achieving higher survival rate in this category of patients, providing earlier and more complete reduction of activity of the systemic inflammatory response, and causes the faster stabilisation of haemodynamics and reduction of multiple organ failure symptoms.2 ex

ethod of production of pentaglycidyl ether of glucose and composition based on it for chemical linking of collagen-containing endoprostheses of biological origin // 2563251
FIELD: biotechnologies.SUBSTANCE: invention relates to the method of producing of penta-1,2,3,4,6-(2-glycidyl oxy ethoxy)-ethyl ether of glucose and to its use in the composition for chemical linking of collagen-containing endoprostheses of biological origin that can be used in medicine. In the offered method penta-1,2,3,4,6-(2-glycidyl oxy ethoxy)-ethyl ether of glucose is produced by reaction of D-glucose with 2-{ 2-([vinyloxy]etoxy)methyl}-oxirane in the solvent 1,4-dioxane, 1,2-dimethoxyethane or tetrahydrofuran at 80-96°C in presence of trifluoroacetic acid. The method allows to increase selectivity of formation of penta-1,2,3,4,6-(2-)-ethyl ether of glucose. The offered composition includes penta-1,2,3,4,6-(2-glycidyl oxy ethoxy)-ethyl ether of glucose in water buffer solutions (pH 5.0-8.0) with adding of isoosmolar compounds providing osmolarity of composition in the range 260-310 mosm/l.EFFECT: possibility of efficient linking of collagen-containing biomaterials.5 cl, 10 ex
ethod for prevention of intraoperative lymphohaematogenous intoxication accompanying peritonitis // 2558989
FIELD: medicine.SUBSTANCE: subclavian or jugular vein is catheterised from the left. A catheter is inserted below a point of a thoracic duct inflow to a venous angle. An infusion ozone therapy is conducted through the catheter when inspecting the abdominal cavity at the start of the operation and when rinsing the same at the end of the operation.EFFECT: intraoperative lymphohaematogenous intoxication is prevented by administering the ozonised solutions below the point of the thoracic duct inflow to the venous angle that makes conditions for neutralising the toxins inflowing from it into the venous system and enables avoiding the intraoperative lymphohaematogenous intoxication accompanying peritonitis.1 ex
ethod of treating postinjection infiltrates in oncology patients // 2558469
FIELD: medicine.SUBSTANCE: from the first day a postinjection infiltrate has been found or at a later point in time, the infiltrate is exposed to infrared laser light in a constant magnetic field. The magnetic field strength falls within the range of 20-50 mT; an infrared laser pulse repetition frequency ranges within 80 Hz, whereas a transmission power is 0.25-0.5 W. The infiltrate is exposed to a defocused laser beam in the contact labile or distant labile mode at 0.3 cm for 15-25 seconds. Thereafter, tissues wetted in a hypertonic solution are applied 1-3 times a day. The therapeutic course makes 5-8 daily procedures.EFFECT: shortening the length of the infiltrate resolution ensured by the anti-oedema, anti-inflammatory, restorative effect produced by the exposure that enables normalising the blood and lymph circulation within the infiltrate and all around, and improving local immunity.1 ex
ethod of carrying out premedication in planned surgery // 2557882
FIELD: medicine.SUBSTANCE: phenazepamum 1.0 mg is prescribed per os to patient on the eve of planned operation; then, in pre-narcosis room after catheterisation of peripheral vein suprastinum in dose 0.3 mg/kg of patient's body weight and atropine in dose 0.01 mg/kg of patient's body weight are introduced intramuscularly 30 minutes before operation. After that, solution of dexmedetomidine with concentration 4.0 mkg/ml in dose 1.0 mcg/kg of patient's body weight is introduced by intravenous infusion by syringe-batcher for 10 min.EFFECT: method ensures optimal level of sedation and stability of haemodynamics indexes at the background of reduction of patient's psycho emotional stress and preservation of their contact with medical staff.2 ex

ethod of bone tissue substitution // 2553368
FIELD: medicine.SUBSTANCE: described is a method of bone tissue substitution, in which as a bone-substituting material applied is a biodegradable material of the following composition, wt %: biological hydroxyapatite - 50-52, magnesium phosphate - 30-32, calcium hydrophosphate - 8-10, calcium hydroxide - 4.8-5.3, sodium alginate - the remaining part. As a binding agent applied is casein in the form of an ammonia solution with the ratio of powder mass of the biodegradable material to the ammonia casein solution of 1:1-1.5.EFFECT: reduction of terms and improvement of surgical operation results.4 dwg, 2 tbl, 2 ex
ethod of enhancing hemocirculation in suture belt of interintestinal anastomosis // 2551624
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery, and can be applied for the enhancement of hemocirculation in a suture belt of the interintestinal anastomosis in experiment. For this purpose 0.25% solution of trimecaine is introduced in a dose of 400-88 ml per day into the mesentery of the intestine in the zone of the anastomosis under peritonitis conditions in dogs after the small intestine resection. 500 IU of heparin and a daily dose of an antibiotic are additionally added into the trimecaine solution.EFFECT: method provides the enhancement of hemocirculation in suture belts of the interintestinal anastomosis due to the increase of intramural pressure.2 tbl
Bonding products of aminated polysaccharides // 2549492
FIELD: chemistry.SUBSTANCE: invention relates to chemistry and presents a conjugation product, comprising polysaccharides T1 and T2, where the monosaccharides which form the polysaccharides T1 and T2 are bonded to each other by alpha-1,4-glycosidic links. At least one of the polysaccharides T1 and/or T2 comprises at least one amino group. T1 and T2 are bonded to each other covalently by a linker. T1 and/or T2 carry m groups -(L-A), wherein A is glucosaminoglycan or a derivative of glucosaminoglycan, glucosaminoglycan or a derivative of glucosaminoglycan with fluorescence labels, L is a second linker, by which T1 and/or T2 are covalently bonded to A, and m is at least 1.EFFECT: invention also relates to a pharmaceutical composition, comprising a bonded product; use of the product in medicine and cosmetology and to the method of preparation of the bonded product.22 cl, 5 ex

ethod of treating inaccessible hernia of intervertebral disk // 2549014
FIELD: medicine.SUBSTANCE: interlaminectomy preserving a yellow ligament is performed. A sequestrum is visualised and removed. An EOC-controlled laser light guide is inserted into the intervertebral disk through its injured portion. That is followed by a laser vaporisation of a nucleus pulposus with a 3- or 4-pulse train, power 20 Wt, length 1 s, interval 2 s in a total dose of 940-1,000 J. An operative aid area is filled with Oxiplex® gel from epidural-periradicular-subligamentous direction.EFFECT: method provides preventing postdiskectomy syndrome by preventing epidural fibrosis by preserving the yellow ligaments in a combination with using Oxiplex gel, and recurrent disk hernia by laser disk repair.2 cl, 4 dwg, 1 ex

ethod for preventing intraoperative bleeding caused by preoperative introduction of heparine // 2544805
FIELD: medicine.SUBSTANCE: solution containing fibrin monomer in the concentration of 11 mg/ml and urea in the concentration of 150 mg/ml is introduced intravenously into male rabbits experimentally one hour before the surgical intervention. A dose of fibrin monomer is 0.25 mg/kg.EFFECT: method possess the high effectiveness as both reduces the bleeding volume, but causes the severe haemodynamic disturbances and allergic reactions.2 dwg

ethod of treating mastoid diseases complicated with thrombophlebitis // 2544370
FIELD: medicine.SUBSTANCE: treating mastoid diseases complicated with thrombophlebitis involves removing a pathologically changed bone, opening all mastoid process cells, exposing a sigmoid sinus and puncturing it with removing a thrombus. That is followed by plugging a sinus lumen with High-structure sodium alginate hydrogel matrix with pre-added dioxidine 0.03 g. The matrix surface is coated with Hydrogel Coletex AKL tissue. The antretomastoid cavity walls are covered with the same material, whereas a latex tampon pre-coated with Hydrogel Coletex-ADL tissue is used for plugging.EFFECT: method provides the early generation of granulation tissue, the protective and haemostatic effect in the wound, reduces the length of treatment, prevents early and late complications and thereby improving the patient's quality of life.3 dwg, 2 ex
ethod for preventing and treating colitis in excluded colon // 2544340
FIELD: medicine.SUBSTANCE: 0.5% dihydroquercetin is instilled into the rectum of a patient with temporary colostomy until he/she starts feeling intestinal inflation. The procedure is performed twice a day, daily up until the restorative surgery.EFFECT: method reduces a rate and a degree of colitis manifestations by the local antioxidant, anti-inflammatory effect, unfolding the excluded colon.
ethod of treating purulent-septic complications accompanying acute destructive pancreatitis // 2541269
FIELD: medicine.SUBSTANCE: ozone-oxygen mixture is administered from both sides of a retroperitoneal space into paranephric fat in an amount of up to 500 mg included from each side. The ozone concentration makes 10 mg/l and less. The therapeutic course makes 5-10 sessions every 1-3 days.EFFECT: effective treatment of the given pathology by supplying the ozone-oxygen mixture directly to an arterial trunk that causes its targeted action.3 ex

ethod for surgical treatment of frontal sinusites // 2539372
FIELD: medicine.SUBSTANCE: frontal sinus is approached in a typical location and sanitated. After the sanitation procedure, a bone defect is covered with high-structure hydrogel matrix of sodium alginate, wherein dioxidin 0.03g and ε-aminocapronic acid 0.15g are pre-administered. The sinus is obliterated with MK-9M osteoplastic composition. The approach point is covered with the same matrix, on the top of which the wound is closed completely and coated with Coletex-ADL hydrogel tissue.EFFECT: method provides preventing early and late suppurative complications, promotes preventing intracranial complications, reduces the recovery time by the protective antiseptic, homeostatic, antitoxic properties of the used matrix, which prevents the composition prolapse into the intracranial cavity as a brace.4 dwg, 2 ex
ethod for conservative treatment of external colonic fistulas // 2538175
FIELD: medicine.SUBSTANCE: patients keep a diet with reducing an amount of liquid taken up to 1.5l a day that is compensated by the intravenous administration of solutions an amount and composition of which depends on a degree of water-electrolyte disturbances. Additionally, after bandage removal, the wound and edges of the fistulous passage is 5% potassium permanganate, which is then washed with 3% hydrogen peroxide. A mouth of the fistula and the wound edges are dried. That is followed by an aeration of the mouth of the fistula with a cooled plasma flow of nitrogen monoxide at a depth of 0.5cm in the therapeutic mode of 2000 mg/m3 and exposition of 1.5min. The mouth of the fistula and the wound edges are treated with a plasma flow of nitrogen monoxide in the concentration within the contact area with the wound surface of 1500 mg/m3 and time of exposure of 20 seconds per each 1 cm2 of the surface. The mouth of the fistula and the wound edges are dried. The mouth is packed with the gauze swab. The fistulous wound is exposed to EHF waves with the pure noise spectrum and the provided integral power on the wound surface of 1.5 mcWt along the perimeter of the mouth at 15mm from the fistulous passage for 30 minutes. The swab is removed. The mouth and the surrounding skin is treated with zinc paste and covered with gauze swabs. The further bandages are performed in the similar way as the bandage wets with the intestinal contents, but no more than 2 times a day and at least once every 3 days.EFFECT: safe and effective conservative treatment of the intestinal fistulas at any phase of the wound process that enables avoiding risks of surgical intervention and general anaesthesia by rapid reduction of skin maceration and perifocal inflammation surrounding the mouth and prevents them, stimulates the growths of granulocyte tissue and epithelisation of the fistuous wound.
ethod of treating perforations and disruption of lower one-third of oesophagus // 2536830
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to thoracic surgery, and can be used to close defects of the lower one-third of the oesophagus. A laparotomy and a sagittal diaphragmotomy are performed. The oesophageal wall defect is closed with a single-layer uninterrupted absorbable mass suture. The suture is started from the proximal end of the defect with the first knot tightened into the oesophageal lumen. A fundoplication cuff is created with covering the suture with the stomach. One of the gastric walls is fixed by interrupted sutures surrounding the closed oesophageal defect to form a cavity between the closed oesophageal defect and the gastric wall. The cavity is filled with Coletex ADL hydrogel tissue. The fundoplication cuff is fixed by interrupted sutures circularly to the diaphragm. The pleural spaces, mediastinal and subphrenic space are drained.EFFECT: method provides reducing the time of recovery, reducing a probability of postoperative complications and faster rehabilitation by forming the reliable sutures, long bactericidal effect on the suture area, dividing the pleural space and abdominal cavity.1 ex
ethod for photodynamic processing of scleral bed following endoresection of intraocular new growth // 2536116
FIELD: medicine.SUBSTANCE: endoresection of an intraocular new growth is followed by covering the scleral bed surface with a photosensitising gel (PS gel) containing 0.1% monoethylene diamine monoamide chlorine adipate e6. The PS gel exposure makes 3 minutes. Thereafter, the scleral bed is exposed to laser light at a wave length of 662 nm, light dense of 60 J/cm2, with the fields of 4 mm in diameter in an air medium with the exposure covering the 1.5 mm surrounding tissues. The exposure is circle-wise from the periphery to the centre and covers the adjoining fields by 5% of the area.EFFECT: avoiding the tumour cells remained viable on the scleral bed after the endoresection of the intraocular new growth, eliminating recurrences of tumours and metastases in the remote postoperative period.1 ex
ethod for combined processing of scleral bed following endoresection of intraocular new growth // 2536109
FIELD: medicine.SUBSTANCE: endoresection of an intraocular new growth is followed by covering the scleral bed surface with a photosensitising gel (PS gel) containing 0.1% monoethylene diamine monoamide chlorine adipate e6. The PS gel exposure makes 3 minutes. The residual gel is taken off. An active portion of one needle electrode is intraocularly applied on the scleral bed in parallel with the retinotomy border at 0.5-0.7 mm. The second electrode is applied in parallel to the first one at 3-4 mm to the centre of the scleral bed. That is followed by performing an electrochemical lysis (ECL) at the current intensity of 5 mA for 10 seconds. The electrodes are gradually moved along the scleral bed surface first circle-wise, in parallel to the retinotomy border, then from the periphery to the centre. The ECL covers the entire area of the scleral bed at the current intensity of 5 mA for 10-15 seconds in each position of the electrodes. That is followed by intraocular photodynamic therapy (PDT) along the entire area of the scleral bed with involving the 1.5 mm surrounding tissues. The patient is exposed to laser light at a wave length of 662 nm, power density of 60 J/cm2, by fields of 4 mm in diameter, circle-wise from the periphery to the centre, and involving the adjoining fields by 5% of the area.EFFECT: avoiding the tumour cells remained viable on the scleral bed after the endoresection of the intraocular new growth, eliminating recurrences of tumours and metastases in the remote postoperative period.1 ex
ethod of treating angiodysplasias // 2535105
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to vascular surgery and concerns treating vascular dysplasia. That is ensured by a contrast phlebography of an angiodysplastic lesion by a percutaneous administration of 76% urografin heated to 36.4-37.6°C. That is followed by administering a sclerosing preparation an amount of which (Vsc) is calculated empirically by derived formula Vsc=Vug·0.8, wherein Vug is an amoung of urografin required for visualising a vascular pattern of angiodysplasia. Further, a finger compression of angiodysplasia is performed for at least three minutes.EFFECT: method enables calculating precisely the required and adequate amount of the sclerosing preparation that provides the effective treatment of angiodysplasia, including difficult ones with minimum side effects.
 
2551100.
Up!